FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997519752> ?p ?o ?g. }

• W1997519752 endingPage "944" @default.
• W1997519752 startingPage "936" @default.
• W1997519752 abstract "Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial compared vorapaxar and placebo in 12,944 high-risk patients with non–ST-segment elevation acute coronary syndrome. We explored aspirin (ASA) use and its association with outcomes. Kaplan-Meier event rates were compared in groups defined by ASA dose (low, medium, and high). Landmark analyses with covariate adjustment were performed for 0 to 30, 31 to 180, and 181 to 365 days. Of 12,515 participants, 7,523, 1,049, and 3,943 participants were treated with low-, medium-, and high-dose ASA at baseline, respectively. Participants enrolled in North America versus elsewhere were more often treated with a high dose at baseline (66% vs 19%) and discharge (60% vs 3%). Unadjusted cardiovascular death, myocardial infarction, stroke, hospitalization for ischemia, or urgent revascularization event rates tended to be higher with higher baseline ASA (18.45% low, 19.13% medium, and 20.27% high; p for trend = 0.15573). Unadjusted and adjusted hazard ratios (95% confidence intervals) for effect of vorapaxar on cardiovascular (unadjusted p for interaction = 0.065; adjusted p for interaction = 0.140) and bleeding (unadjusted p for interaction = 0.915; adjusted p for interaction = 0.954) outcomes were similar across groups. Landmark analyses showed similar safety and efficacy outcomes with vorapaxar and placebo by ASA dose at each time point except for 0 to 30 days, when vorapaxar tended to be worse for efficacy (hazard ratio 1.13, 95% confidence interval 0.89 to 1.44, p for interaction = 0.0157). In conclusion, most TRACER participants were treated with low-dose ASA, although a high dose was common in North America. High-dose participants tended to have higher rates of ischemic and bleeding outcomes. Although formal statistical testing did not reveal heterogeneity in vorapaxar's effect across dose subgroups, consistent trends support use of low-dose ASA with other antiplatelet therapies." @default.
• W1997519752 created "2016-06-24" @default.
• W1997519752 creator A5000539924 @default.
• W1997519752 creator A5004091916 @default.
• W1997519752 creator A5005158159 @default.
• W1997519752 creator A5021191954 @default.
• W1997519752 creator A5024015419 @default.
• W1997519752 creator A5025162040 @default.
• W1997519752 creator A5033070568 @default.
• W1997519752 creator A5037527199 @default.
• W1997519752 creator A5039432822 @default.
• W1997519752 creator A5039450208 @default.
• W1997519752 creator A5048065442 @default.
• W1997519752 creator A5060370891 @default.
• W1997519752 creator A5062843291 @default.
• W1997519752 creator A5063591215 @default.
• W1997519752 creator A5075973255 @default.
• W1997519752 creator A5087154648 @default.
• W1997519752 creator A5090147492 @default.
• W1997519752 date "2014-03-01" @default.
• W1997519752 modified "2023-09-22" @default.
• W1997519752 title "Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)" @default.
• W1997519752 cites W2024352468 @default.
• W1997519752 cites W2085260510 @default.
• W1997519752 cites W2093279552 @default.
• W1997519752 cites W2108064339 @default.
• W1997519752 cites W2117677020 @default.
• W1997519752 cites W2134322421 @default.
• W1997519752 cites W2140501627 @default.
• W1997519752 cites W2159370853 @default.
• W1997519752 cites W3030817736 @default.
• W1997519752 cites W303795847 @default.
• W1997519752 doi "https://doi.org/10.1016/j.amjcard.2013.11.052" @default.
• W1997519752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24444781" @default.
• W1997519752 hasPublicationYear "2014" @default.
• W1997519752 type Work @default.
• W1997519752 sameAs 1997519752 @default.
• W1997519752 citedByCount "17" @default.
• W1997519752 countsByYear W19975197522014 @default.
• W1997519752 countsByYear W19975197522015 @default.
• W1997519752 countsByYear W19975197522016 @default.
• W1997519752 countsByYear W19975197522017 @default.
• W1997519752 countsByYear W19975197522019 @default.
• W1997519752 countsByYear W19975197522020 @default.
• W1997519752 countsByYear W19975197522021 @default.
• W1997519752 crossrefType "journal-article" @default.
• W1997519752 hasAuthorship W1997519752A5000539924 @default.
• W1997519752 hasAuthorship W1997519752A5004091916 @default.
• W1997519752 hasAuthorship W1997519752A5005158159 @default.
• W1997519752 hasAuthorship W1997519752A5021191954 @default.
• W1997519752 hasAuthorship W1997519752A5024015419 @default.
• W1997519752 hasAuthorship W1997519752A5025162040 @default.
• W1997519752 hasAuthorship W1997519752A5033070568 @default.
• W1997519752 hasAuthorship W1997519752A5037527199 @default.
• W1997519752 hasAuthorship W1997519752A5039432822 @default.
• W1997519752 hasAuthorship W1997519752A5039450208 @default.
• W1997519752 hasAuthorship W1997519752A5048065442 @default.
• W1997519752 hasAuthorship W1997519752A5060370891 @default.
• W1997519752 hasAuthorship W1997519752A5062843291 @default.
• W1997519752 hasAuthorship W1997519752A5063591215 @default.
• W1997519752 hasAuthorship W1997519752A5075973255 @default.
• W1997519752 hasAuthorship W1997519752A5087154648 @default.
• W1997519752 hasAuthorship W1997519752A5090147492 @default.
• W1997519752 hasConcept C126322002 @default.
• W1997519752 hasConcept C127413603 @default.
• W1997519752 hasConcept C142724271 @default.
• W1997519752 hasConcept C164705383 @default.
• W1997519752 hasConcept C204787440 @default.
• W1997519752 hasConcept C207103383 @default.
• W1997519752 hasConcept C27081682 @default.
• W1997519752 hasConcept C2777628954 @default.
• W1997519752 hasConcept C2777698277 @default.
• W1997519752 hasConcept C2780645631 @default.
• W1997519752 hasConcept C44249647 @default.
• W1997519752 hasConcept C500558357 @default.
• W1997519752 hasConcept C50382708 @default.
• W1997519752 hasConcept C71924100 @default.
• W1997519752 hasConcept C78519656 @default.
• W1997519752 hasConceptScore W1997519752C126322002 @default.
• W1997519752 hasConceptScore W1997519752C127413603 @default.
• W1997519752 hasConceptScore W1997519752C142724271 @default.
• W1997519752 hasConceptScore W1997519752C164705383 @default.
• W1997519752 hasConceptScore W1997519752C204787440 @default.
• W1997519752 hasConceptScore W1997519752C207103383 @default.
• W1997519752 hasConceptScore W1997519752C27081682 @default.
• W1997519752 hasConceptScore W1997519752C2777628954 @default.
• W1997519752 hasConceptScore W1997519752C2777698277 @default.
• W1997519752 hasConceptScore W1997519752C2780645631 @default.
• W1997519752 hasConceptScore W1997519752C44249647 @default.
• W1997519752 hasConceptScore W1997519752C500558357 @default.
• W1997519752 hasConceptScore W1997519752C50382708 @default.
• W1997519752 hasConceptScore W1997519752C71924100 @default.
• W1997519752 hasConceptScore W1997519752C78519656 @default.
• W1997519752 hasFunder F4320307776 @default.
• W1997519752 hasIssue "6" @default.
• W1997519752 hasLocation W19975197521 @default.
• W1997519752 hasLocation W19975197522 @default.
• W1997519752 hasOpenAccess W1997519752 @default.

• next